HAEMATO AG
ISIN: DE000A289VV1
WKN: A289VV
15 February 2022 02:45PM

HAEMATO adds a new generation test device to its portfolio

HAEMATO AG · ISIN: DE000A289VV1 · EQS - Company News
Country: Germany · Primary market: Germany · EQS NID: 1280801


DGAP-Media / 15.02.2022 / 14:45

Schönefeld, 15 February 2022 - HAEMATO PHARM GmbH ("HAEMATO"), a 100% subsidiary of HAEMATO AG (ISIN: DE000289VV1), is expanding its medical device portfolio in the fight against Corona virus. In addition to the already introduced Point-of-Care (PoC) PCR device, HAEMATO is now also marketing the Mini Dock, an alternative PoC device that sets a benchmark in terms of price.

The Mini Dock offers a cost and resource-efficient alternative to laboratory PCR analyses. The test principle of nucleic acid amplification uses the same method as PCR testing, but instead of using heat, the amplification is carried out with the help of enzymes. This speeds up the testing process and makes it significantly less expensive than PCR analysis in the laboratory. At 999 euros per device and 12.50 euros per test, HAEMATO offers a cost-effective alternative to the more expensive PCR devices. The Mini Dock has only the size of a palm and the weight of a smartphone while the specificity is comparable to the specificity of PCR tests. This allows pharmacies, surgeries and hospitals throughout the country to be equipped. Further development for home diagnostics is a possibility, as is networking with many players in the health sector through the modular software platform HAEMATO.AI. By using an interface to the Robert Koch Institute, certificates for tested persons can already be issued here.

According to the Federal Ministry of Health of Germany, the testing with PoC-NAT devices is suitable to verify positive antigen rapid test results. In addition, the Federal Ministry of Health in Germany states on its website, that the tests are very well suited in situations when a reliable test result is needed within a short time, such as testing in emergency rooms, outpatient clinics and care facilities or even for travel.

Patrick Brenske, CEO of HAEMATO AG, says: "From a sales point of view, it is crucial that NAT tests for doctors' surgeries, dentists' surgeries, pharmacies, medical laboratories, rescue and aid organisations as well as test centres of the public health service in Germany are currently remunerated. These places can offer a NAT test free of charge to a person who is entitled to a test and bill them through the respective Association of Statutory Health Insurance Physicians (Kassenärztliche Vereinigung). Additionally, federal states such as Lower Saxony or Baden-Württemberg subsidise the purchase of the NAT testing devices."

With the speed of a rapid test and the precision of a molecular diagnostic method, the device can detect positive samples for the Corona virus within 15 minutes. This allows faster treatment decisions for the benefit of the patient and early isolation of infected individuals to improve infection control.

Both the PoC-NAT devices and classic rapid antigen tests as well as FFP2 masks are available for order and immediate delivery via the website www.schnelltest-antigen.de.

About HAEMATO:

HAEMATO AG was founded in 1993 and is a pharmaceutical company with a focus on trading in high-priced special pharmaceuticals (with a therapeutic focus on oncology, HIV, rheumatology, and other chronic diseases) as well as the development and distribution of medical products and own brands, particularly in the area of "Lifestyle & Aesthetics". HAEMATO AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange. Further information can be found at www.haemato.de.

Contact:
HAEMATO AG, Investor Relations
Telefon: +49 (0)30 897 30 86 70
ir@haemato.ag


End of Media Release


Issuer: HAEMATO AG
Key word(s): Trades

15.02.2022 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: HAEMATO AG
Lilienthalstraße 5c
12529 Schönefeld
Germany
Phone: +49 (0)30 897 30 86 70
Fax: +49 (0)30 897 30 86 79
E-mail: ir@haemato.ag
Internet: www.haemato.ag
ISIN: DE000A289VV1
WKN: A289VV
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange
EQS News ID: 1280801

 
End of News DGAP Media

1280801  15.02.2022 

fncls.ssp?fn=show_t_gif&application_id=1280801&application_name=news&site_id=boersengefluester_html

Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.

The most important financial data at a glance
  2018 2019 2020 2021 2022 2023 2024e
Sales1 274,12 197,84 238,33 285,04 248,14 281,51 278,00
EBITDA1,2 9,96 1,90 3,31 12,64 9,66 11,50 11,10
EBITDA-Margin3 3,63 0,96 1,39 4,43 3,89 4,09 3,99
EBIT1,4 8,50 -18,68 1,63 11,16 8,30 10,57 10,30
EBIT-Margin5 3,10 -9,44 0,68 3,92 3,35 3,76 3,71
Net Profit (Loss)1 6,28 -1,17 -4,83 6,53 8,19 7,74 7,30
Net-Margin6 2,29 -0,59 -2,03 2,29 3,30 2,75 2,63
Cashflow1,7 0,56 -2,76 14,67 14,05 19,73 -3,32 8,40
Earnings per share8 2,70 -0,50 -1,02 1,35 1,57 1,48 1,40
Dividend per share8 1,00 0,00 0,00 1,10 1,20 0,00 0,00
Quelle: boersengefluester.de and Company information
Explanation

1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de

Auditor: Harry Haseloff

All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.

INVESTOR-INFORMATION
©boersengefluester.de
Haemato
WKN ISIN Legal Type Marketcap IPO Recommendation Plus Code
A289VV DE000A289VV1 AG 55,43 Mio € 05.12.2005 - 9F4M9H86+67
* * *
PE 2025e PE 10Y-Ø BGFL-Ratio Shiller-PE PB PCF KUV
6,75 14,80 0,46 5,83 0,37 -16,70 0,20
Dividends
Dividend '2022
in €
Dividend '2023
in €
Dividend '2024e
in €
Div.-Yield '2024e
in %
1,20 0,00 0,00 0,00%
Financial calendar
Annual General Meeting Q1-figures Q2-figures Q3-figures Annual press conference
16.07.2024 23.04.2024
Performance
Distance 60-days-line Distance 200-days-line Performance YtD Performance 52 weeks IPO
Last Price (EoD)
-1,85%
10,60 €
ATH 94,40 €
-20,72% -32,05% -60,15% -58,59% +0,00%

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.
          Qualitätsjournalismus · Made in Germany © 2024          
The news manufactory

Good luck with all your investments

Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.

Contact

Idea & concept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2024 by Gereon Kruse #BGFL